Nervous System News and Research

Latest Nervous System News and Research

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from AUGMENT/COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) for the treatment of Chronic Obstructive Pulmonary Disease (COPD), delivered in the Pressair™ inhaler (Genuair® outside the USA).

2 May 2013

Forest Laboratories, Almirall report positive topline results from AUGMENT COPD

Forest Laboratories, Inc. and Almirall, S.A. today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate, delivered in the Pressair (Genuair outside the USA) inhaler.

2 May 2013

Scientists reveal that exposure to everyday noise may affect cardiovascular system

Exposure to noise, for example from road traffic, may adversely affect the cardiovascular system. Until now, underlying mechanisms linking noise to elevated cardiovascular risk have rarely been explored in epidemiological studies. Scientists of Helmholtz Zentrum München have now shown that exposure to noise during everyday life influences heart rate variability, i.e. the ability of the heart to adjust the rate at which it beats to acute events.

2 May 2013

New report finds sharp increase in emergency department visits involving adverse reactions to zolpidem

A new report shows that the number of emergency department visits involving adverse reactions to the sleep medication zolpidem rose nearly 220 percent from 6,111 visits in 2005 to 19,487 visits in 2010.

2 May 2013

PTSD study: Individuals with childhood abuse history have distinct changes in gene activity patterns

Abuse during childhood is different. A study of adult civilians with PTSD (post-traumatic stress disorder) has shown that individuals with a history of childhood abuse have distinct, profound changes in gene activity patterns, compared to adults with PTSD but without a history of child abuse.

2 May 2013

BioLineRx starts enrollment in Phase I/II trial of BL-8020 for treatment of HCV

BioLineRx, a biopharmaceutical development company, announced today enrollment of the first patient in a Phase I/II trial for BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus.

29 Apr 2013

New treatment strategy for patients with CMT disease on the horizon

A potential new treatment strategy for patients with Charcot-Marie-Tooth disease is on the horizon, thanks to research by neuroscientists now at the University at Buffalo's Hunter James Kelly Research Institute and their colleagues in Italy and England.

29 Apr 2013

CHMP recommends approval of NUEDEXTA for treatment of pseudobulbar affect

Avanir Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect, irrespective of neurologic cause.

29 Apr 2013

Antihistamine drugs work by preventing histamine from attaching to H1 receptors

Itchy eyes, scratchy throat, running nose--it's allergy season! What triggers these allergic reactions, and how do allergy medications work?

26 Apr 2013

Geisinger and Bucknell celebrates opening of Autism and Developmental Medicine Center

Officials from Geisinger Health System and Bucknell University celebrated the grand opening of the Autism and Developmental Medicine Center, a national model for implementing guidelines for early diagnosis, medication management and treatment options for children with developmental disorders.

26 Apr 2013

Neuralstem gets approval from FDA for dosing cohort patients in NSI-189 Phase Ib in MDD treatment

Neuralstem, Inc. announced that it has received approval from the Food and Drug Administration (FDA) to begin dosing the third and final cohort of patients in its ongoing Phase Ib to test the safety of NSI-189 in the treatment of major depressive disorder (MDD).

26 Apr 2013

Renal denervation reduces blood pressure for patients not responding to drug therapy

Up to 10 per cent of patients with high blood pressure are resistant to treatment, which puts them at increased risk of cardiovascular events, including heart attacks. Clinical trials show that catheter-based renal denervation reduces blood pressure in patients who do not respond to conventional drug therapy.

26 Apr 2013

Omeros presents clinical data of OMS302 on reducing pupil constriction during ILR at ASCRS meeting

Omeros Corporation today reported analyses of Phase 2 and Phase 3 clinical data showing the favorable impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement.

25 Apr 2013

ORAEs increase costs of care, hospital stays and risks of readmission and mortality, research finds

Pacira Pharmaceuticals, Inc. today announced the publication of findings from a retrospective analysis of more than 37,000 patients who underwent common inpatient surgeries at a large, 26-hospital healthcare system and received opioids for postsurgical pain management.

25 Apr 2013

Individual hydroxymethylcytosine molecules in DNA detected by new method involving chemical modification and nanopore analysis

Changes in the bases that make up DNA act as markers, telling a cell which genes it should read and which it shouldn’t. In the journal Angewandte Chemie, a British team has now introduced a new method that makes it possible to enrich the rare gene segments that contain the modified base hydroxymethylcytosine and to identify individual hydroxymethylcytosine molecules in DNA. Such modifications are associated with autoimmune diseases and cancer.

24 Apr 2013

Researchers develop sensor system to assess how blasts impact human body

Improvised explosive devices are becoming a global problem for the U.S. armed forces. To prevent injuries to soldiers and provide better care to those who are injured, the U.S. military is striving to better understand how blasts impact the human body.

24 Apr 2013

Methodist Hospital will soon have new brain and pituitary tumor treatment center

Brain and pituitary tumor patients will soon have access to a state-of-the-art facility at The Methodist Hospital, a result of a $10 million dollar commitment from a Houston oil executive.

24 Apr 2013

Investigational treatment for ALS passes early phase clinical trial for safety

An investigational treatment for an inherited form of Lou Gehrig's disease has passed an early phase clinical trial for safety, researchers at Washington University School of Medicine in St. Louis and Massachusetts General Hospital report.

24 Apr 2013

BD receives FDA approval for second prefilled injectable drug

BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.

From BD (Becton, Dickinson and Company) 24 Apr 2013

Researchers uncover potential new way to fight obesity-related illness

A potential new way to fight obesity-related illness has been uncovered, thanks to serendipitous research led by investigators at the Case Western Reserve University School of Medicine.

24 Apr 2013

Nervous System News and Research

Latest Nervous System News and Research

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Forest Laboratories, Almirall report positive topline results from AUGMENT COPD

Scientists reveal that exposure to everyday noise may affect cardiovascular system

New report finds sharp increase in emergency department visits involving adverse reactions to zolpidem

PTSD study: Individuals with childhood abuse history have distinct changes in gene activity patterns

BioLineRx starts enrollment in Phase I/II trial of BL-8020 for treatment of HCV

New treatment strategy for patients with CMT disease on the horizon

CHMP recommends approval of NUEDEXTA for treatment of pseudobulbar affect

Antihistamine drugs work by preventing histamine from attaching to H1 receptors

Geisinger and Bucknell celebrates opening of Autism and Developmental Medicine Center

Neuralstem gets approval from FDA for dosing cohort patients in NSI-189 Phase Ib in MDD treatment

Renal denervation reduces blood pressure for patients not responding to drug therapy

Omeros presents clinical data of OMS302 on reducing pupil constriction during ILR at ASCRS meeting

ORAEs increase costs of care, hospital stays and risks of readmission and mortality, research finds

Individual hydroxymethylcytosine molecules in DNA detected by new method involving chemical modification and nanopore analysis

Researchers develop sensor system to assess how blasts impact human body

Methodist Hospital will soon have new brain and pituitary tumor treatment center

Investigational treatment for ALS passes early phase clinical trial for safety

BD receives FDA approval for second prefilled injectable drug

Researchers uncover potential new way to fight obesity-related illness

Everything you need to know about epilepsy eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Nervous System News and Research

Latest Nervous System News and Research

Everything you need to know about epilepsy eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in